ARCTURUS THERAPEUTICS HOLDIN (ARCT) Stock Price, Quote, News and Overview
NASDAQ:ARCT - Nasdaq - US03969T1097 - Common Stock - Currency: USD
ARCT Quote, Performance and Key Statistics
ARCTURUS THERAPEUTICS HOLDIN
NASDAQ:ARCT (2/4/2025, 8:27:05 PM)
After market: 15.7 -0.35 (-2.18%)16.05
+0.25 (+1.58%)
The current stock price of ARCT is 16.05 USD. In the past month the price decreased by -10.54%. In the past year, price decreased by -59.51%.
ARCT Latest News, Press Releases and Analysis
Arcturus Therapeutics Announces Appointment of Moncef Slaoui, Ph.D., as Chair Designate
Meiji Seika Pharma Receives Approval for Adding Domestic Manufacturing Sites in Japan for KOSTAIVE®, a Self-amplifying mRNA Vaccine Against COVID-19
Arcturus Therapeutics to Present at Guggenheim Securities SMID Cap Biotech Conference
Arcturus Therapeutics Announces Initiation of Phase 1 H5N1 Flu Vaccine Trial
Arcturus Therapeutics Announces Initiation of Dosing in Phase 2 Multiple Ascending Dose Studies for Cystic Fibrosis (CF) and Ornithine Transcarbamylase (OTC) Deficiency
ARCT Competitors/Peers
Symbol | Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 18.77 | 335.67B | ||
| AMGN | AMGEN INC | 15.04 | 155.36B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 945.65 | 124.20B | ||
| GILD | GILEAD SCIENCES INC | 22.12 | 122.12B | ||
| REGN | REGENERON PHARMACEUTICALS | 15.34 | 76.60B | ||
| ARGX | ARGENX SE - ADR | N/A | 38.95B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | N/A | 34.95B | ||
| BNTX | BIONTECH SE-ADR | N/A | 28.08B | ||
| ONC | BEIGENE LTD-ADR | N/A | 23.76B | ||
| NTRA | NATERA INC | N/A | 23.00B | ||
| BIIB | BIOGEN INC | 8.73 | 20.76B | ||
| UTHR | UNITED THERAPEUTICS CORP | 15.52 | 15.78B |
Related stock screener links
About ARCT
Company Profile
Arcturus Therapeutics Holdings, Inc. operates as a late-stage clinical mRNA medicines and vaccine company, which engages in the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. The company is headquartered in San Diego, California and currently employs 180 full-time employees. The company went IPO on 2013-05-22. The firm is focused on the development of infectious disease vaccines and significant opportunities within liver and respiratory rare diseases. In addition to its messenger RNA (mRNA) platform, its lipid nanoparticle (LNP) delivery system, LUNAR, has the potential to enable multiple nucleic acid medicines, and its self-amplifying mRNA technology (Self-Transcribing and Replicating RNA (STARR), technology) has the potential to provide longer-lasting RNA and sustained protein expression at lower dose level. The company is leveraging its LUNAR platform and its nucleic acid technologies to develop and advance a pipeline of mRNA-based vaccines and therapeutics for infectious diseases and rare genetic disorders with significant unmet medical needs. Its COVID-19 vaccine candidate, which is based on its STARR technology platform is through Phase II clinical trials.
Company Info
ARCTURUS THERAPEUTICS HOLDIN
10628 Science Center Dr Ste 250
San Diego CALIFORNIA 92121 US
CEO: Joseph E. Payne
Employees: 180
Company Website: https://arcturusrx.com/
Investor Relations: https://ir.arcturusrx.com/
Phone: 18589002660
ARCT FAQ
What is the stock price of ARCT?
The current stock price of ARCT is 16.05 USD.
What is the symbol for ARCTURUS THERAPEUTICS HOLDIN stock?
The exchange symbol of ARCTURUS THERAPEUTICS HOLDIN is ARCT and it is listed on the Nasdaq exchange.
On which exchange is ARCT stock listed?
ARCT stock is listed on the Nasdaq exchange.
Is ARCT a good stock to buy?
Always make your own analysis. On these pages you can find a full technical and fundamental analysis report for ARCT, which may be a starting point for your analysis. You can also find the financials, news, analyst ratings and estimates here, which can be used to increase your understanding of ARCT.
Does ARCT stock pay dividends?
ARCT does not pay a dividend.
What is the Price/Earnings (PE) ratio of ARCT?
ARCT does not have a PE ratio as the earnings reported over the last twelve months were negative (-2.22).
What is the Short Interest ratio of ARCT stock?
The outstanding short interest for ARCT is 20.34% of its float.
ARCT Technical Analysis
ARCT Fundamental Analysis
ChartMill assigns a fundamental rating of 4 / 10 to ARCT. ARCT scores quite bad on profitability, while its financial health is fine. Not spectacular, but in line with the averages.
ARCT Financial Highlights
Over the last trailing twelve months ARCT reported a non-GAAP Earnings per Share(EPS) of -2.22. The EPS decreased by -159.84% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -16.9% | ||
| ROE | -23.92% | ||
| Debt/Equity | 0 |
ARCT Ownership and Analysts
ChartMill assigns a Buy % Consensus number of 86% to ARCT. The Buy consensus is the average rating of analysts ratings from 17 analysts.
For the next year, analysts expect an EPS growth of -135.59% and a revenue growth 0.98% for ARCT